comprehensive -WSS

comprehensive

author：explore 2025-09-05 18:31:36 - browse：3

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA clears Verve to begin U.S. study of gene

hotspot

explore

WSS

Smaller biotechs seek to piggyback on weight loss drug boom

Cassava Sciences’ Alzheimer’s clinical trials should be halted

The problems with dementia villages

New CMS data security rules will hurt Medicare, Medicaid research

How AI can help patients find reliable information about doctors

Study on Amgen’s bispecific immunotherapy produces positive data

Wikipedia

comprehensive

Wikipedia

Supreme Court strikes down use of affirmative action

UnitedHealth, Optum discontinue NaviHealth name

State Dept. review finds Biden bears some blame for Afghanistan failures

UnitedHealth, Optum discontinue NaviHealth name

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Trump demands the U.S. pay no more for drugs than other countries … again

How AI can help patients find reliable information about doctors

After affirmative action ruling, medical educators look to 'holistic review'

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Wikipedia

J&J lung cancer data amount to new salvo against AstraZeneca

Roche drug slashes death risk in early

Hospitals are piloting generative AI tools as regulators play catch

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Measles policy set amid Florida outbreak alarms vaccine proponents

STAT Readout Newsletter: Biotech news today

knowledge

hotspot

explore

hotspot